Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase I for Primary CNS Lymphoma.

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed.

Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "MEK Inhibitors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for MEK Inhibitors ...

Researchers at Tel Aviv University have developed a new platform using polymeric nanoparticles to deliver drug pairs to ...

INR:1965. blackjack 42 upgrades With the explosion of tyrosine kinase inhibitors and the proliferation of PD-1, where will the development of new drugs go?

INR:6203. how many t20 world cup england won 27% of advanced patients responded to RAF/MEK inhibitors for all cancer types in Phase 1 trial pub ...